News
ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 2, 2019: Benelux’ largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), July 25th, 2019: hematologists and multiple myeloma (blood cancer) patients in the UK will have access to Dutch developed diagnostic test MMprofilerTM with SKY92 algorithm through the...
ROTTERDAM en SAN DIEGO (Verenigde Staten), 23 juli 2019: de hematologie afdeling van het Erasmus Medisch Centrum (EMC) is wereldwijd het eerste ziekenhuis dat elke multipel myeloom (bloedkanker) patiënt een innovatieve diagnostische service...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), July 23rd, 2019: the academic hematology department of Erasmus Medical Center (EMC) is globally the first hospital to offer every multiple myeloma (blood cancer) patient an...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 26th, 2019: the Rotterdam headquartered diagnostics company has been granted CAP (College of American Pathologists) accreditation, following its CLIA (Clinical Laboratory Improvement Amendments) certification in...
ROTTERDAM en SAN DIEGO (Verenigde Staten), 13 juni 2019: een aanzienlijk aantal bloedkanker (multipel myeloom) patiënten kunnen beter beslissen over een behandeling als er meer informatie over hun diagnose beschikbaar komt voor hen...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), June 13th, 2019: a substantial number of blood cancer (multiple myeloma) patients could make more informed decisions on their treatment if more information becomes available for...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), November 28, 2018: an international consortium of researchers and physicians is the first to distinguish three risk groups in multiple myeloma (ultra-low, intermediate and high-risk patients)...
ROTTERDAM en SAN DIEGO (USA), 27 september, 2018: Rijksdienst voor Ondernemend Nederland (RVO), een onderdeel van het ministerie van Economische Zaken en Klimaat, kent, middels Innovatiekrediet, € 2,7 miljoen toe aan de ontwikkeling...
ROTTERDAM (the Netherlands) and SAN DIEGO (US), September 27, 2018: Netherlands Enterprise Agency (“Rijksdienst voor Ondernemend Nederland”), a part of the Ministry of Economic Affairs and Climate Policy, grants through a financial loan...
ROTTERDAM, the Netherlands and SAN DIEGO, USA, August 1, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels about a novel machine learning concept that derives...
ROTTERDAM en SAN DIEGO (USA), 30 juli, 2018: Wetenschappelijk tijdschrift Nature Communications publiceerde 27 juli 2018 het onderzoekspaper van Joske Ubels over het GESTURE [1] algoritme dat individuele kankerpatiënten koppelt aan een specifieke...
ROTTERDAM, the Netherlands and SAN DIEGO USA, July 30th, 2018: Renowned scientific journal Nature Communications published July 27th, 2018 a research paper by Joske Ubels on the algorithm GESTURE [1] that links individual...
SKY92 risk stratification at relapse provides additional prognostic information for standardrisk Multiple Myeloma patients RNA-Seq based risk stratification in Multiple Myeloma patients validates SKY92 as a high-risk marker in the COMMPASS trial...
Rotterdam, the Netherlands, January 31, 2018 – SkylineDx today announced a strategic collaboration with Mayo Clinic to develop novel diagnostic tests which will improve clinical decision making for melanoma patients. For SkylineDx, the...
First Validation of SKY92 Prognostic Signature in Bortezomib-Thalidomide-Dexamethasone (VTD) Setting Additional Data Yield Key Insights into Biology of Multiple Myeloma and Inform Design of Myeloma UK (MUK) Nine OPTIMUM Trial Rotterdam, the...
Poster Presentation at ISPOR European Congress Demonstrates Cost-savings and HealthGenerating Benefits of SKY92 Rotterdam, the Netherlands and Laguna Hills, CA, November 13, 2017 – SkylineDx announced new data from the 20th Annual European...
ICR to Use SkylineDx’s MMprofiler™ Gene-Based Prognostic Signature in Phase IIb MUK nine High-risk Trial in Multiple Myeloma Rotterdam, the Netherlands and Laguna Hills, CA, October 12, 2017 – SkylineDx today announced that...
